Driven by accelerating diagnosis of ATTR cardiomyopathy, sustained reliance on cost-effective chemotherapy, and rapid uptake of disease-modifying therapies in North America, the global amyloidosis therapeutics market is on a strong growth trajectory, expanding by 2033, as imaging-led case identification, regulatory fast-tracking, and broader reimbursement convert rare-disease innovation into routine clinical care worldwide.
